^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Solid Tumor)
New
Title:

entrectinib (Rozlytrek ®) is accepted for use within NHSScotland

Excerpt:
entrectinib (Rozlytrek) is accepted for use within NHSScotland...as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

An updated analysis of the clinical efficacy and safety of entrectinib in NTRK fusion-positive sarcoma

Published date:
11/18/2020
Excerpt:
After a median follow-up of 17.74 months (95% CI 9.95–22.57), the confirmed ORR was 56.3% (95% CI 29.9–80.3...The majority of patients with sarcoma experienced a reduction in tumour lesion size, including those with CNS metastases at baseline...Entrectinib continued to achieve clinically meaningful, durable responses, demonstrating overall efficacy in patients with NTRK fusion-positive sarcoma.